US venture capital investment in biotechnology companies fell during the second quarter, but remained near recent record-breaking levels as investors continued to support larger funding rounds for some biotechnology startups – a trend that's ongoing in the third quarter with Series A rounds totaling $57m for Oncorus Inc. and $55m for Fulcrum Therapeutics.
A hundred biotech companies raised $1.7bn during the second quarter of 2016 compared with 127 that raised $2.1bn during the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
